Leuko: Funding, Investors & Team (Oct 2026)
Leuko Labs has created a non-invasive device for monitoring white blood cells. Assessing white blood cells is crucial in many medical situations, such as managing chemotherapy and detecting serious infections. Currently, this test is invasive and not easily accessible, requiring patients to travel for blood draws and lab tests. With Leuko Labs' PointCheck device, immunosuppressed patients can now undergo more frequent testing, leading to better quality of life and clinical outcomes.
Leuko has raised $9.5M across 2 funding rounds on record, the most recent an undisclosed round of $4.5M announced in Jul 2024.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Leuko Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Leuko Funding Rounds
Leuko raised $5.0M in a Series A announced in Sep 2022.
1.8 years later, an undisclosed round of $4.5M was announced in Jul 2024.
Leuko Founders and Leadership Team
Contact details for the Leuko team: 2 of 2 have an email address on file.
Start 14-day free trial →Leuko Funding Compared to Other Biotechnology Startups
Leuko's latest round of $4.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Leuko in Biotechnology and Boston
Companies Similar to Leuko
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Leuko Funding FAQs
What does Leuko do?
Leuko Labs has created a non-invasive device for monitoring white blood cells. Assessing white blood cells is crucial in many medical situations, such as managing chemotherapy and detecting serious infections. Currently, this test is invasive and not easily accessible, requiring patients to travel for blood draws and lab tests. With Leuko Labs' PointCheck device, immunosuppressed patients can now undergo more frequent testing, leading to better quality of life and clinical outcomes.
How much funding has Leuko raised?
Leuko has raised $9.5M across 2 rounds on record. The most recent is an undisclosed round of $4.5M announced in Jul 2024.
When did Leuko last raise funding?
Leuko's most recent funding round on record is an undisclosed round of $4.5M, announced in Jul 2024.
Who founded Leuko?
FundedIQ lists Ian Butterworth (Founder) at Leuko.
Who is the CEO of Leuko?
Carlos Castro Gonzalez is listed as CEO at Leuko.
Where is Leuko headquartered?
Leuko is based in Boston, Massachusetts, United States.
How many employees does Leuko have?
Leuko is in the 11-50 employee band.
How does Leuko's funding compare to other Biotechnology startups?
Leuko's latest round of $4.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Leuko Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Leuko is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.